2-hydroxybenzylamine acetate

Preclinical

2-hydroxybenzylamine acetate is one of 43 therapeutic programs targeting Alzheimer disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer DiseaseNot yet recruiting

Alzheimer DiseasePreclinical

Not yet recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Eisai

Approved

1 2

Dayvigo

Eisai

Approved

1 3

Avandia

Estrace

Aleve

Avelox

Epidiolex

Rifadin

Victoza

Cialis

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalNot yet recruiting

Alzheimer Disease

NCT06432166

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients

Not yet recruiting·MMTI Biotech Inc·Preclinical·NCT06432166·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 2-hydroxybenzylamine acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 2-hydroxybenzylamine acetate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — MTI Biotech Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMTI Biotech Inc

2-hydroxybenzylamine acetate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News